BioNTech Faces a Summer of Reckoning as Vaccine Revenues Wane and Oncology Data Takes Center Stage

BioNTech enters a critical stretch with no single event to anchor investor sentiment. The German biotech’s stock closed at €80.20 on Friday, down 1.41% on the day and off 4.86% for the week, yet the monthly picture shows a 7.36% gain. That seesaw reflects a company in flux: its pandemic vaccine franchise is shrinking, its founders are preparing to leave, and its future hinges on a sprawling oncology pipeline that has yet to produce a commercial product. Over 12 months the shares have given up 17.66%, and the gap to the 52-week high of €105.80 — set on January 22 — stands at 24.2%.

Morgan Stanley added to the near-term pressure on July 12 by cutting its price target to $119, down from an earlier level that was above the broader consensus of $122.13 recorded by Yahoo Finance at the start of July. The trigger: a COVID-19 vaccine revenue forecast that lagged market expectations. First-quarter 2026 numbers underscore how thin the non-vaccine earnings base remains — revenue of $118.1 million accompanied a net loss of $494.6 million. The stock now trades just above its 50-day moving average of €79.38 but well below the 200-day line of €85.13, with a neutral RSI of 48.5 and an annualized 30-day volatility of 28.71% that suggests no shortage of potential swings.

The leadership shake-up adds a layer of strategic uncertainty. Founders Ugur Sahin and Özlem Türeci plan to exit by the end of 2026 to launch a new venture combining mRNA with artificial intelligence. When their departure was announced in March, the stock briefly plunged as much as 20%, wiping roughly $50 billion off market capitalization. For the full year 2025, BioNTech reported revenue of €2.9 billion and a net loss of €1.1 billion, while sitting on a cash pile of €17.2 billion. This year the company expects research and development spending of €2.2 billion to €2.5 billion — far less than the €22–25 billion the primary article erroneously stated, which appears to be a typo; the secondary source suggests heavy but unspecified R&D costs — and plans to run 15 Phase 3 oncology studies. The FDA has been reviewing denecimig since September 2025.

Should investors sell immediately? Or is it worth buying BioNTech?

The mood among bulls and bears crystallizes around those oncology programs. Optimists point to more than 25 Phase 2 and Phase 3 trials, including 13 registration-enabling studies and novel combination therapies across tumor types. Encouraging Phase 2 data for gotistobart in platinum-resistant ovarian cancer showed overall survival improvements, hinting at a chemotherapy-free option. Meanwhile, the global ROSETTA-Lung-02 study delivered positive signals for pumitamig combined with chemotherapy in non-small-cell lung cancer — data now feeding into an ongoing Phase 3. If the pipeline continues to deliver, analysts see the consensus price target of €107.05 as achievable. Skeptics counter that the gap between early data and commercial reality remains wide. The legacy dependence on COVID vaccine revenue creates structural volatility, and heavy research spending is burning through cash. A delay in any clinical timeline could tighten the balance sheet further. Combined with the pending founder exit, execution risk is unusually high.

On the legal front, BioNTech and Pfizer scored a victory earlier this month at the Unified Patent Court, defeating Promosome in a dispute over COVID-19 vaccine patents. The win bolsters the company’s intellectual property position even as the commercial importance of that product fades. Separately, the future of BioNTech’s German manufacturing sites has become a talking point. Moderna CEO Stéphane Bancel said in mid-June he would consider investing in factories that BioNTech plans to close, provided a suitable partnership with the federal government materializes. The interest comes as other drugmakers, including Eli Lilly, scale back German expansion plans over regulatory concerns.

With no clear near-term catalyst, the market is drifting. The next confirmed milestone is the Q2 earnings call on August 4, where investors will look for updates on study progress, spending, and the leadership transition. Until then, the stock will be guided by the flow of clinical readouts rather than one marquee event. Should those data prove convincing and free of safety issues, a gradual recovery toward the 100-day moving average of €81.78 looks plausible. Disappointment, on the other hand, could push the shares back toward the 52-week low of €68.35 set on March 10. For now, BioNTech is a company caught between fading vaccine revenue and an unproven oncology bet — and the summer will decide which narrative prevails.